The secretory activities of meibomian glands are regulated by the autonomic nervous system. The change in density and activity of autonomic nerves in meibomian glands during menopause play an important role in the pathogenesis of dry eye. In view of this, we established a dry eye rat model by removing the bilateral ovaries. We used neuropeptide Y and vasoactive intestinal polypeptide as markers of autonomic neurotransmitters. Our results showed that the concentration of estradiol in serum significantly decreased, the density of neuropeptide Y immunoreactivity in nerve fibers significantly increased, the density of vasoactive intestinal polypeptide immunoreactivity in nerve fibers significantly decreased, and the ratio of vasoactive intestinal polypeptide/neuropeptide Y positive staining significantly decreased. These results suggest that a decrease in ovary activity may lead to autonomic nervous system dysfunction, thereby affecting the secretory activity of the meibomian gland, which participates in sexual hormone imbalance-induced dry eye.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190857 | PMC |
| http://dx.doi.org/10.3969/j.issn.1673-5374.2012.35.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dupilumab induced ocular surface diseases: an analysis of FAERS database, literature review and disease-gene interaction networks.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, China.
Background: Adverse events (AE) in dupilumab induced ocular surface diseases (DIOSD) have raised concerns regarding its safety. The objective of this study was to evaluate DIOSD by employing database analysis and clinical case review, along with mechanism analysis.
Research Design And Methods: Database AE data were extracted from FAERS from 2017 Quarter 1 (Q1) to 2023 Q1.
Clinical practice patterns in the management of dry eye disease: A TFOS international survey 2023-4.
Ocul Surf
December 2024
Centre for Ocular Research and Education (CORE), School of Optometry and Vision Science, University of Waterloo, Canada; Optometry and Vision Science Research Group, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom; Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, New Zealand.
Aims: To understand current clinical management of dry eye disease (DED), based on its perceived severity and subtype by practitioners across the world.
Methods: The content of the anonymous survey was chosen to reflect the DED management strategies reported by the Tear Film and Ocular Surface Society (TFOS) 2 Dry Eye Workshop (DEWS II). Questions were designed to ascertain practitioner treatment choice, depending on the subtype and severity of DED.
Evaluating the impact of smoking on the risk of dry eye disease: a two-sample Mendelian randomization study.
Sci Rep
December 2024
Eye Center, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuhan, 430060, Hubei, China.
Dry Eye Disease (DED) is a common condition worldwide, with smoking being recognized as a possible aggravating factor. Although observational studies have indicated a potential correlation, the findings have been inconclusive. In the study, Mendelian randomization (MR) analysis is used to investigate this potential causal relationship.
View Article and Find Full Text PDFBlood component therapy for dry eye disease: a systematic review and network meta-analysis.
Front Med (Lausanne)
December 2024
Department of Ophthalmology, Zhangye People's Hospital Affiliated to Hexi University, Zhangye, China.
Objective: Blood component therapy has shown promising potential as an emerging treatment for dry eye disease; however, it remains unclear which specific blood component is the most effective. This study aims to compare the efficacy of different blood components in the treatment of dry eye disease through a network meta-analysis, with the goal of providing the latest and most reliable evidence for clinical practice.
Methods: We conducted a systematic search of the PubMed, Web of Science, Cochrane, Embase, and Scopus databases, with the search concluding on June 1, 2024.
AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial.
Ocul Surf
December 2024
AZURA Ophthalmics, Tel-Aviv, Israel.
Background: Contact lens discomfort (CLD) is a common problem for CL wearers, and patients with CLD often have changes in meibomian gland function and structure. In a Phase 2 trial AZR-MD-001 0.5% (AZR) ophthalmic ointment improved meibomian gland dysfunction (MGD) in non-lens wearers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!